Myriad Genetics is planning a broader Precise MRD launch in breast cancer following AACR readouts. The company’s focus is an ultrasensitive circulating tumor DNA test intended to quantify risk of relapse and support treatment escalation or de-escalation strategies. The reported emphasis on MRD aligns with the ongoing shift toward measurable residual disease as a decision point rather than a purely prognostic marker. By pairing assay sensitivity with therapy-intensity decisions, the program aims to improve clinical precision for patients at varying relapse risk. For biotech and diagnostics companies, the expansion plan highlights competitive intensity around ctDNA-based MRD platforms and the importance of evidence packages that demonstrate clinical utility beyond analytical performance.